- Home
- DSGR vs VRDN Comparison
DSGR vs VRDN Comparison
Compare DSGR & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGR
- VRDN
- Stock Information
- Founded
- DSGR 1952
- VRDN 2006
- Country
- DSGR United States
- VRDN United States
- Employees
- DSGR N/A
- VRDN N/A
- Industry
- DSGR Industrial Machinery/Components
- VRDN Medical Specialities
- Sector
- DSGR Industrials
- VRDN Health Care
- Exchange
- DSGR Nasdaq
- VRDN Nasdaq
- Market Cap
- DSGR 1.5B
- VRDN 1.5B
- IPO Year
- DSGR N/A
- VRDN N/A
- Fundamental
- Price
- DSGR $31.09
- VRDN $18.87
- Analyst Decision
- DSGR Buy
- VRDN Strong Buy
- Analyst Count
- DSGR 1
- VRDN 11
- Target Price
- DSGR $41.00
- VRDN $38.80
- AVG Volume (30 Days)
- DSGR 49.6K
- VRDN 877.5K
- Earning Date
- DSGR 10-30-2025
- VRDN 11-11-2025
- Dividend Yield
- DSGR N/A
- VRDN N/A
- EPS Growth
- DSGR N/A
- VRDN N/A
- EPS
- DSGR 0.08
- VRDN N/A
- Revenue
- DSGR $1,928,948,000.00
- VRDN $305,000.00
- Revenue This Year
- DSGR $11.30
- VRDN N/A
- Revenue Next Year
- DSGR $4.13
- VRDN $35,092.81
- P/E Ratio
- DSGR $337.72
- VRDN N/A
- Revenue Growth
- DSGR 13.48
- VRDN 5.90
- 52 Week Low
- DSGR $21.87
- VRDN $9.90
- 52 Week High
- DSGR $41.47
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- DSGR 46.51
- VRDN 52.46
- Support Level
- DSGR $30.24
- VRDN $18.12
- Resistance Level
- DSGR $31.62
- VRDN $20.51
- Average True Range (ATR)
- DSGR 0.89
- VRDN 0.94
- MACD
- DSGR -0.26
- VRDN -0.01
- Stochastic Oscillator
- DSGR 23.88
- VRDN 34.66
About DSGR Distribution Solutions Group Inc.
Distribution Solutions Group Inc is an industrial distributor of maintenance and repair supplies. It has three operating segments namely Lawson, TestEquity, and Gexpro Services, of which key revenue is derived from the TestEquity segment. The TestEquity segment is a distributor of test and measurement equipment and solutions, electronic production supplies, and tool kits from its manufacturer partners supporting the technology, aerospace, defense, automotive, electronics, education and medical industries.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).